Core Viewpoint - The stock of Giant Bio (02367) has experienced a decline of over 6%, currently trading at 39.8 HKD, with a transaction volume of 513 million HKD, following the approval of its medical device product, a recombinant type I α1 collagen lyophilized fiber [1] Group 1: Company Developments - Giant Bio's "recombinant type I α1 collagen lyophilized fiber" has received approval as a Class III medical device, marking it as China's first recombinant type I natural sequence collagen facial injection product [1] - Huatai Securities maintains its profit forecast for the company, projecting a net profit for 2025-2027 [1] Group 2: Market Performance - CooBeauty's online sales performance during the first phase of the Double Eleven shopping festival has been relatively weak, with an estimated 10% year-on-year decline in online revenue for the second half of the year, leading to an overall online revenue growth rate of approximately 5% for the year [1] - In contrast, Collyre's online revenue is expected to achieve a high growth rate of about 40% for the year, while offline business is anticipated to maintain steady growth [1] - The revenue growth forecast for the company is expected to slow down to 12% by 2025 [1]